The ₹1,450-crore public issue opened on October 21 and closes on October 23, 2026. While one brokerage recommends subscribing, another takes a neutral stance, citing occupancy trends, capacity expansion and regulatory risks.

Paras Healthcare IPO Opens Amid Mixed Brokerage Views

Paras Healthcare's ₹1,450-crore initial public offering (IPO) opened for subscription on Wednesday, October 21, 2026, attracting differing recommendations from brokerages. While Ventura has assigned a ‘Subscribe’ rating, SBI Securities has adopted a ‘Neutral’ stance, advising investors to monitor hospital occupancy, expansion execution and regulatory developments.

The company operates hospitals focused on specialised and high-acuity medical care, positioning it to benefit from increasing demand for organised healthcare in North India and selected underserved markets. However, analysts have highlighted that the company's future performance will depend on how efficiently it expands capacity, improves utilisation and manages the risks associated with its patient mix.

The IPO will remain open until October 23, 2026.

Bed Occupancy Improves, Supporting Operating Performance

One of the key factors supporting the investment case is the improvement in hospital utilisation. According to SBI Securities, Paras Healthcare's bed occupancy increased to 61.8% in FY26 from 50.8% in FY25.

Occupied bed days rose 25.8% year-on-year to 338,321 during FY26, indicating an increase in the number of days patients occupied the company's hospital beds.

Higher occupancy can improve the utilisation of existing hospital infrastructure and support revenue growth without requiring an equivalent increase in capital expenditure. Hospitals typically have substantial fixed costs, including staffing, equipment, maintenance and facility expenses. Better utilisation can therefore contribute to operating leverage, provided pricing and costs remain manageable.

However, occupancy alone does not determine profitability. Revenue per occupied bed, specialty mix, treatment complexity, payer mix and operating expenses will also influence financial performance. Investors should assess whether the improvement can be sustained as the company adds capacity.

Expansion Plans and Specialised Healthcare Offerings

Paras Healthcare's growth strategy includes increasing capacity at existing facilities, particularly in Gurugram and Ludhiana, alongside opportunities for further expansion.

Ventura highlighted the company's potential for brownfield expansion at its existing hospitals. It has also acquired land adjacent to its Panchkula facility for future development and may consider selective acquisitions where these could strengthen regional presence or improve operating efficiency.

The company's key specialties include cardiac sciences, oncology, neurosciences, gastro sciences, orthopaedics and sports injury, and renal sciences. These areas often require advanced equipment, specialist medical professionals and substantial infrastructure investment.

Its presence across North India, Bihar and Jharkhand gives it exposure to markets where organised private healthcare penetration remains relatively low. If demand grows and new capacity is commissioned efficiently, the company could increase patient volumes and strengthen its regional position.

Nevertheless, hospital expansion involves execution risks. Construction delays, higher-than-expected project costs, difficulty recruiting medical professionals and slower-than-anticipated patient ramp-up could affect returns on invested capital.

SBI Securities Maintains Neutral Rating

SBI Securities has assigned a Neutral rating to the IPO, acknowledging the company's improving operating metrics and growth opportunities while highlighting several risks.

The brokerage expects future growth to be supported by rising occupancy at newer hospitals, expansion of high-acuity specialties and planned capacity additions. However, it has emphasised the company's dependence on government schemes and public sector undertaking (PSU) patients.

A significant reliance on institutional or government-linked patient volumes can expose hospitals to changes in reimbursement rates, payment cycles and scheme-related policies. Regulatory changes and pricing restrictions may also affect revenue and margins.

SBI Securities has indicated that it would prefer to track occupancy levels, execution of upcoming capacity additions and regulatory developments over the next few quarters following listing before taking a more constructive view.

Ventura Recommends Subscription

Ventura has assigned a Subscribe rating, pointing to Paras Healthcare's expansion opportunities and its presence in markets with relatively lower penetration of organised private healthcare.

The brokerage sees potential for the company to expand existing facilities, develop its Panchkula land parcel and selectively pursue acquisitions that improve regional scale or operating leverage.

The investment case rests on the possibility that increasing healthcare demand, better utilisation and a stronger specialty mix could support long-term growth. However, these opportunities depend on successful execution and do not guarantee future profitability or share-price appreciation.

The difference between the two brokerage recommendations reflects the balance between Paras Healthcare's growth potential and the uncertainty surrounding expansion, patient mix and regulatory conditions.

Paras Healthcare IPO: Key Issue Details

The public issue is a book-built offering comprising a fresh issue and an offer for sale.

• Total issue size: ₹1,450 crore

• Fresh issue: ₹500 crore, comprising 72.15 lakh shares

• Offer for sale: ₹950 crore, comprising approximately 1.37 crore shares

• Price band: ₹660–₹693 per share

• Lot size: 21 shares

• Minimum investment at the upper price band: ₹14,553

• IPO opening date: October 21, 2026

• IPO closing date: October 23, 2026

• Book-running lead manager: JM Financial Ltd.

• Registrar: MUFG Intime India Pvt. Ltd.

The fresh issue component will bring new capital into the company, while the offer-for-sale portion will allow existing shareholders to sell part of their holdings. Proceeds from an offer for sale generally go to the selling shareholders rather than the company.

Investors should review the prospectus for the intended use of fresh issue proceeds, financial performance, outstanding liabilities and risk factors before making an application.

Subscription Status: Early Response Remains Limited

As of 12:20 p.m. on October 21, the IPO had been subscribed 0.09 times, according to the figures available in the reported update.

The retail investor portion was subscribed 0.43 times, while the non-institutional investor (NII) category was subscribed 0.04 times. No bids had been recorded in the qualified institutional buyer (QIB) category at that time.

These figures represent an early snapshot from the first day of bidding and may change materially before the issue closes. Investors should check the latest exchange subscription data rather than rely on the initial figures when assessing demand.

Subscription levels can provide information about investor interest, but they do not independently establish a company's valuation, business quality or likely post-listing performance.

Key Risks Investors Should Monitor

1. Occupancy sustainability: The improvement to 61.8% in FY26 is encouraging, but investors should examine whether occupancy continues to rise, particularly at newer hospitals.

2. Expansion execution: Capacity additions at Gurugram and Ludhiana, along with future development at Panchkula, could support growth. Delays or cost overruns may reduce returns.

3. Patient and payer mix: Dependence on government schemes and PSU patients exposes the company to reimbursement and policy-related risks.

4. Capital intensity: Hospitals require significant investment in infrastructure, medical equipment and specialised personnel. Expansion must generate adequate returns to justify the capital deployed.

5. IPO valuation: Investors should compare the offer valuation with earnings, cash flows, debt, growth prospects and listed healthcare peers. The price band alone does not indicate whether the IPO is attractively valued.

Market Outlook

Paras Healthcare enters the public market with improving occupancy, a specialty-focused operating model and opportunities to expand in underserved healthcare markets. These factors underpin Ventura's positive recommendation, while SBI Securities' Neutral rating highlights the need for evidence that growth can be sustained without excessive execution or regulatory risk.

The key monitorables after listing will be hospital-level occupancy, revenue growth, operating margins, cash generation, expansion timelines and the returns earned on new capacity. The company's ability to convert rising patient volumes into durable earnings and cash flow will be more important over the long term than first-day subscription figures alone.

Investors should evaluate the IPO in the context of their risk appetite, investment horizon and the company's disclosed valuation. Brokerage recommendations represent differing assessments, not assurances of listing gains or future returns.